Jared Jaynes
Optometrist · Overland Park, KSNPI 1356606867
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 24 manufacturers reported payments, led by Glaukos Corporation at 34.6% of the total. Reporting peaked in 2023 at $2,022 and has fallen 79.9% since, to $407 in 2025. Among optometrist clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 135 payments — averaging $39.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$2K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Sun Pharmaceutical Industries Inc.$444
- AbbVie$352
- Bausch & Lomb Americas Inc.$271
- Dompe US, Inc.$212
- plus $1K from 18 others
What the payments were for
- Consulting fees$1,50028%
- Travel & lodging$87917%
- Food & beverage$2,91655%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 13 | $1,834 |
| Johnson & Johnson Surgical Vision, Inc. | 7 | $1,150 |
| Sun Pharmaceutical Industries Inc. | 21 | $444 |
| AbbVie(2 entities) | 21 | $352 |
| Bausch & Lomb Americas Inc. | 13 | $271 |
| Dompe US, Inc. | 9 | $212 |
| Oyster Point Pharma, Inc. | 10 | $192 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $152 |
| Kala Pharmaceuticals, Inc. | 7 | $102 |
| Alcon | 5 | $91 |
| Optos, Inc. | 1 | $73 |
| Biotissue Holdings Inc. | 2 | $60 |
| Novartis | 3 | $54 |
| Rxsight Inc | 2 | $45 |
| Coopervision Inc. | 2 | $42 |
| Eyevance Pharmaceuticals LLC | 2 | $36 |
| Thea Pharma Inc. | 2 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $31 |
| Astellas Pharma US Inc | 1 | $27 |
| Shire North American Group Inc | 1 | $23 |
| Lombart Brothers, Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Aerie Pharmaceuticals, Inc. | 1 | $18 |
| Alcon Research LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,295 in reported general payments places this provider in the 95th percentile of 567 optometrist providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 76 | $85,027 |
| MieboPerfluorohexyloctane/Pf | 16 | $14,665 |
| TyrvayaVarenicline Tartrate | 16 | $14,120 |
| Loteprednol Etabonate | 76 | $12,114 |
| Cyclosporine | 25 | $12,025 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 22 | $4,950 |
| Prednisolone Acetate | 134 | $4,870 |
| Fluorometholone | 32 | $2,702 |
| Difluprednate | 21 | $2,459 |
| Latanoprost | 178 | $2,089 |
| ValacyclovirValacyclovir Hcl | 37 | $1,189 |
| Doxycycline Hyclate | 34 | $1,115 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 106 | $1,023 |
| Timolol Maleate | 111 | $1,002 |
| Brimonidine Tartrate | 11 | $417 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $352 | $85,02776 claims |
| Bausch & Lomb Americas Inc.Miebo | $271 | $14,66516 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $192 | $14,12016 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $152 | $12,11476 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 567 optometrist providers in Kansas.
Other optometrist in Overland Park
- Vincent PennipedeOverland Park$16K
- Mark SiefkesOverland Park$11K
- Katherine PainterOverland Park$7K
- Anthony BrandOverland Park$5K
- Jay BurlingameOverland Park$5K
- Neal EylarOverland Park$5K
- Dawn BircherOverland Park$4K
- Liron BittanOverland Park$4K
- L BeslerOverland Park$4K
- Buffie MockOverland Park$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.